A Phase 2 Intensification Study of BIT225, a Human Immunodeficiency Virus-1 Vpu Inhibitor, in HIV-1 Infected Individuals Initiating Combination Antiretroviral Therapy (cART).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs BIT 225 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Biotron
- 31 Jul 2017 Planned End Date changed from 31 Oct 2017 to 4 Jan 2018.
- 27 Jul 2017 According to a Biotron media release, early results from this trial are anticipated in October 2017 after trial completion.
- 27 Jul 2017 According to a Biotron media release, status changed from recruiting to active, no longer recruiting.